1A-O1-1520 PDF
IP-MSを用いたFGFR2の部位特異的リン酸化解析
Gene amplification and somatic mutations in fibroblast growth factor receptor 2 (FGFR2) contribute to development of malignant tumors. In particular, abnormal activation of FGFR2 signaling has been linked with several types of human cancers such as lung, gastric, ovarian and endometrial carcinomas. It is thought that FGFR2 is a potential target for novel anti-cancer agents and many drugs are now under clinical trials to make clinical benefit in cancer therapy. In this study, we validated the combined immunoprecipitation and mass spectrometric approach to monitor the site specific phosphorylation of FGFR2 expressed in tumor cells, which are addicted to FGF signaling by either amplification or active mutations of FGFR2. In addition, we evaluated the effect of lenvatinib and sorafenib, which are kinase inhibitors, on site specific phosphorylation of FGFR2.